[Form 4] Medpace Holdings, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Medpace Holdings, Inc. (MEDP) director Robert O. Kraft reported an option exercise and share sale. On 11/14/2025, he exercised a stock option for 6,472 shares of common stock at an exercise price of $54.99 per share, increasing his directly held shares. On the same day, he sold 6,472 shares of common stock at a weighted average price of $591.85 per share, in multiple trades priced between $588.98 and $596.543. After these transactions, he reported owning 833 shares of Medpace common stock directly and no remaining derivative securities from this option.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kraft Robert O.

(Last) (First) (Middle)

C/O MEDPACE HOLDINGS, INC.

5375 MEDPACE WAY

(Street)

CINCINNATI OH 45227

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Medpace Holdings, Inc. [ MEDP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/14/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/14/2025		M		6,472	A	$54.99	7,305	D
Common Stock	11/14/2025		S		6,472	D	$591.85(1)	833	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$54.99	11/14/2025		M			6,472	(2)	05/17/2026	Common Stock	6,472	$0	0	D

Explanation of Responses:

1. The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $588.98 to $596.543. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

2. The option vested in full on May 14, 2020.

Remarks:

	/s/ Stephen P. Ewald, Attorney-in-Fact for Robert O. Kraft	11/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Medpace (MEDP) report on November 14, 2025?

Medpace director Robert O. Kraft exercised a stock option for 6,472 shares of common stock and sold 6,472 shares of common stock on 11/14/2025.

At what prices did the Medpace (MEDP) director exercise and sell shares?

He exercised a stock option at an exercise price of $54.99 per share and sold 6,472 shares at a weighted average price of $591.85 per share, with individual sale prices ranging from $588.98 to $596.543.

How many Medpace (MEDP) shares does the reporting person own after the transaction?

Following the reported transactions, Robert O. Kraft beneficially owned 833 shares of Medpace common stock directly.

What happened to the Medpace (MEDP) stock option reported in this Form 4?

The stock option to acquire 6,472 shares at $54.99 per share was fully exercised on 11/14/2025. After the exercise and related sale, the number of derivative securities reported from this option was 0. The option had vested in full on May 14, 2020.

What role does the reporting person hold at Medpace (MEDP)?

The reporting person, Robert O. Kraft, is identified as a director of Medpace Holdings, Inc.